Showing 1911-1920 of 3020 results for "".
- Daily Imaging Boosts NMSC Treatment Success: Analysishttps://practicaldermatology.com/news/daily-imaging-boosts-nmsc-treatment-success-analysis/2468003/Image-guided superficial radiation therapy (IGSRT) was associated with a 99% cure rate for non-melanoma skin cancer (NMSC) when delivered with daily imaging, which allows for adaptive changes based on tumor depth fluctuations. Researchers for a recent retrospective study looked at the rol
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f
- Study Aims to Define Photosensitivity Diagnosis in Atopic Dermatitishttps://practicaldermatology.com/news/study-aims-define-photosensitivity-diagnosis-atopic-dermatitis/2467967/A new study aims to refine diagnostic criteria for photosensitivity in patients with atopic dermatitis (AD). “Previous reports have characterized photosensitivity in AD, but with differences in terminology and criteria,” the authors noted, suggesting a need for better guidance. The
- Topical Skin Introduces Hydrating Facial Cleanserhttps://practicaldermatology.com/news/topical-skin-introduces-hydrating-facial-cleanser/2467858/Topical Skin announced the launch of the Hydrating Facial Cleanser, formulated with ceramide, botanicals, and oleosomes and designed to provide a gentle yet effective cleanse while supporting the skin's barrier, resulting in a hydrated and refreshed complexion. Unlike some cleansers that
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Study: Vegan Nutraceutical Improves Hair Health in Plant-Based Dietershttps://practicaldermatology.com/news/study-vegan-nutraceutical-improves-hair-health-plant-based-dieters/2467690/A recent clinical study suggested that a novel vegan nutraceutical supported hair health in women following plant-based diets. Seeking to address the nutrient deficiencies that can affect hair growth and quality in this population, researchers for the single-blind prospective study conduc
- Consensus Statement: New Reporting Measures Aim to Improve CSCC Researchhttps://practicaldermatology.com/news/consensus-statement-new-reporting-measures-aim-improve-cscc-research/2467669/A new consensus statement from an expert panel supports the creation of standardized guidelines for retrospective studies on cutaneous squamous cell carcinoma (CSCC). "Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology a
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu
- sNDA Submitted for Roflumilast Foam 0.3% for Scalp and Body Psoriasishttps://practicaldermatology.com/news/snda-submitted-roflumilast-foam-03-scalp-and-body-psoriasis/2467457/A supplemental New Drug Application (sNDA) has been submitted for ZORYVE (roflumilast) foam 0.3%, a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis, Arcutis Biotherapeutics, Inc., announce